Phenoxybenzamine
| 證據等級: L5 | 預測適應症: 2 個 |
目錄
Phenoxybenzamine: From Pheochromocytoma to Primary Hereditary Glaucoma
One-Sentence Summary
Phenoxybenzamine is a non-selective, irreversible α-adrenergic receptor antagonist, historically used for pheochromocytoma preoperative management and neurogenic bladder dysfunction. The TxGNN model predicts it may be effective for Primary Hereditary Glaucoma, but currently no clinical trials and no publications support this direction — this is a model-prediction-only signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available (no original indications recorded) |
| Predicted New Indication | Primary Hereditary Glaucoma |
| TxGNN Prediction Score | 99.55% |
| Evidence Level | L5 |
| US Market Status | 未上市 (Not marketed) |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this evidence pack. Based on known pharmacology, phenoxybenzamine is a non-selective, irreversible α-adrenergic receptor antagonist, clinically used for pheochromocytoma preoperative blood pressure control and neurogenic voiding dysfunction.
Primary hereditary glaucoma (largely infantile/congenital glaucoma) is pathologically driven by trabecular meshwork developmental abnormalities (e.g., CYP1B1 mutations), which has no established mechanistic link to α-adrenergic signaling. The TxGNN high score here appears to reflect knowledge-graph topological similarity rather than a genuine pharmacological relationship.
Notably, phenoxybenzamine’s known mydriatic (pupil-dilating) side effect could theoretically precipitate or worsen angle-closure pathology, meaning the mechanistic direction may actually work against, rather than for, this indication. This directional inconsistency further weakens the plausibility of the prediction.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
US Market Information
No NDA/license records available — this drug is not currently marketed in the reference regulatory database (未上市, 0 licenses).
Safety Considerations
Please refer to the package insert for safety information.
(Note: TFDA label warnings/contraindications are currently a blocking data gap (DG001) and DDI data was not found — these must be resolved before any safety evaluation can proceed.)
Conclusion and Next Steps
Decision: Hold
Rationale: This candidate has zero clinical trials, zero literature support, and no verified mechanistic rationale connecting the drug’s α-adrenergic antagonism to hereditary glaucoma pathophysiology — it is L5, model-prediction-only evidence, and the drug’s known mydriatic effect raises a plausible safety concern (risk of angle closure) rather than supporting the indication.
To proceed, the following is needed:
- TFDA label warnings/contraindications (DG001 — currently blocking; required before S1 safety review)
- Confirmed mechanism of action data (DG002)
- Preclinical or mechanistic studies establishing a credible link between α-adrenergic blockade and hereditary glaucoma pathology
- At minimum, case reports or observational data before considering any further evaluation
- Given the directional conflict (mydriasis risk in angle-closure-prone eyes), an ophthalmology safety assessment specifically addressing IOP/angle-closure risk
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.